BTCC
/
BTCC Square
/
Global Cryptocurrency
/
HeartFlow Stock Surges 14% on FDA Approval for Plaque Analysis Algorithm
HeartFlow Stock Surges 14% on FDA Approval for Plaque Analysis Algorithm
9
2
BTCCSquare news:
HeartFlow's shares soared 14% following the U.S. Food and Drug Administration's approval of its HeartFlow Plaque Analysis algorithm. The advanced diagnostic tool, now available for commercial use, leverages 3D renderings and color-coded plaque visualization to improve detection accuracy by 21% compared to its predecessor.
The product's clinical validation draws from a dataset of 273,000 patients, positioning it as a potential game-changer in cardiovascular diagnostics. This regulatory milestone propelled the stock upward even as the broader S&P 500 index dipped slightly during the session.
By:
